Systems, methods, and kits for diagnostics and treatment of viral respiratory infection

Abstract

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

1 . A method for treating a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the method comprises administering a composition to the patient, wherein the composition comprises an anti-androgen. 
     
     
         2 . The method of  claim 1 , wherein the anti-androgen is enzalutamide or any deuterated form thereof. 
     
     
         3 . The method of  claim 1 , wherein the method further comprises administering an anti-thyroid medication, a thyroid receptor inhibitor, a TGF-β inhibitor or a combination thereof. 
     
     
         4 . The method of  claim 3 , wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, SSKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof. 
     
     
         5 . The method of  claim 3 , wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof. 
     
     
         6 . The method of  claim 3 , wherein the TGF-β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof. 
     
     
         7 . The method of  claim 1 , wherein the method further comprises administering a furin inhibitor. 
     
     
         8 . The method of  claim 7 , wherein the furin inhibitor is selected from α1-PDX, Acyclic mini-PDX, Cyclic mini-PDX, OMTKY3 (variant A15R,T17K,L18R), 6R, D6R, D9R, H5N1 derived peptide, Ac-RXXT-NH2, H2N-C8-RXXT, chloromethylketone, Decanoyl-Arg-Val-Lys-Arg-chloromethylketone, Dec-RVKR-CMK, TACE inhibitor, Naphthofluorescein, phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide or a combination thereof. 
     
     
         9 . A method for treating a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the method comprises administering to the patient an anti-thyroid medication, a thyroid receptor inhibitor, a TGF-β inhibitor or a combination thereof. 
     
     
         10 . The method of  claim 9 , wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, SSKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof. 
     
     
         11 . The method of  claim 9 , wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof. 
     
     
         12 . The method of  claim 9 , wherein the TGF-β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof. 
     
     
         13 . The method of  claim 9 , wherein the method further comprises administering a retinoid X receptor antagonist. 
     
     
         14 . The method of  claim 13 , wherein the retinoid X receptor antagonist is selected from LG100754, AGN195393, Ro26-5405, LG101506, PA451, PA452, B1-1003, B1-1005, SR11179, UVI3003, Danthron, Rhein, β-Apo-13-carotenone, R-Etodolac, Sulindac sulfide, K-80003, K-8008, Triptolide, TRC4, NSC-640358, Fluvastatin, Pitavastatin, HX531 or a combination thereof. 
     
     
         15 . The method of  claim 9 , wherein the patient also has prostate cancer. 
     
     
         16 . The method of  claim 9 , wherein the method further comprises administering agents that counter the effect of androgens. 
     
     
         17 . The method of  claim 16 , wherein the agents that counters the effect of androgens are sex hormone-binding globulin (SHBG) stimulators. 
     
     
         18 . The method of  claim 9 , wherein the method further comprises administering an antigonadotropin. 
     
     
         19 . The method of  claim 9 , wherein the method further comprises administering a mineralocorticoid or a glucocorticoid. 
     
     
         20 . The method of  claim 9 , wherein the method further comprises administering an insulin sensitizing medication. 
     
     
         21 . The method of  claim 9 , wherein the method further comprises administering a vaccine or immunogens against androstenedione. 
     
     
         22 . A composition used to treat of a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the composition comprises an anti-androgen, an anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. 
     
     
         23 . The composition of  claim 22 , wherein the composition is formulated with a carrier or delivery vehicle optimized for delivery to the lung. 
     
     
         24 . The composition of  claim 23 , wherein the carrier or delivery vehicles is selected from liposomes, non-ionic liposomes, niosomes, novasome I, erythromycin-Zn complex, microspheres, nanoparticles, solid lipid nanoparticles or nanoemulsions. 
     
     
         25 . The composition of  claim 22 , wherein the composition is formulated to be administered either orally, nasally, topically, intramuscularly, intravenously or by inhalation. 
     
     
         26 . The composition of  claim 22 , wherein the anti-androgen is enzalutamide or any deuterated form thereof. 
     
     
         27 . The composition if  claim 22 , wherein the anti-thyroid medication is selected from sodium iodide, potassium iodide, colloidal iodine, tapazole, methimazole, sodium iodide-i-131, Iodotope, iosat, Northyx, Tapazole, Propylthiouracil, PropylThyracil, PTU, SSKI, ThyroSafe, ThyroShield, iOSAT, Sodium iodide 131I, Hicon or a combination thereof. 
     
     
         28 . The composition of  claim 22 , wherein the thyroid receptor inhibitor is selected from NH-3, tetraiodothyroacetic acid or a combination thereof. 
     
     
         29 . The composition of  claim 22 , wherein the TGF-β inhibitor is selected from M7824, bintrafusp alfa, galunisertib, SAR439459, NIS793, PF-06952229, vactosertib, AVID200, ARGX-115, ABBV-151, trabedersen, VTX-002, ACE-1332, SRK-181 or a combination thereof. 
     
     
         30 . A composition used to treat of a patient with or a patient at risk of developing a SARS-CoV-2 infection, wherein the composition comprises an anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof.